Synthesize Bio, Inc.

Based in Seattle, Synthesize Bio, Inc. specializes in advanced generative AI technology, enabling biopharmaceutical firms to predict gene expression outcomes and enhance drug development processes through innovative solutions. Founded in 2023, Synthesize Bio, Inc. focuses on utilizing generative AI to advance biomedical research.

The company is headquartered in Seattle, US. It raised USD 10. 00 mn in a Seed round on September 16, 2025, led by Madrona Venture Group with participation from several investors including AI2 Incubator and Inner Loop Capital. This funding reflects the firm’s commitment to developing sophisticated AI-driven models for drug discovery.

Synthesize Bio's core offerings involve generative AI models that predict gene expression outcomes for various experiments. Their flagship product, the Generative Genomics Engine, merges proprietary multi-omics data with public biological knowledge to create a detailed map of cellular biology. This technology supports biomarker-driven clinical trials, precision medicine, and pharmacodynamic modeling. Their products are primarily utilized by biopharmaceutical companies and research institutions across North America, Europe, and Asia-Pacific, addressing the demand for innovative solutions in biomedical research.

Synthesize Bio generates revenue through collaborations with biopharmaceutical companies, employing subscription models and contractual agreements for access to their AI technology. These partnerships often involve tailored applications of their models to meet specific client needs. The pricing structure varies based on the project's complexity and scale, reflecting a growing market interest in enhancing drug development processes. Synthesize Bio plans to leverage the recent funding of USD 10.

00 mn to develop AI models for simulating experimental outcomes and generating insights that will support drug discovery. The company aims to introduce new products designed to enhance their generative AI capabilities and expand into targeted markets in Europe and Asia by the end of 2025.